Genmab A/S Stock Forecast
NASDAQ: GMABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
GMAB analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$43.22+19.89%
- Strong buy 1
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Genmab A/S (2026-10-08), 11 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $43.22, with a high estimate of $58.00 and a low estimate of $33.50. The average target implies upside of 19.9% from the current price of $36.05.
The spread between the highest and lowest targets is 73.1%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for GMAB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 8% |
| Buy | 10 | 83% |
| Hold | 1 | 8% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $33.50 | -7.07% |
| Average target | $43.22 | +19.89% |
| High target | $58.00 | +60.89% |